Bionomics & MSD 5th Annual Neuroscience Symposium in October
Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, will again co-host its annual neuroscience symposium with MSD in Adelaide.
The one-day event at the Adelaide Convention Centre on 26 October is entitled The Frontiers of Neuroscience: Feelings & Forgetting featuring world-renowned industry experts. Bionomics and MSD (known as Merck, in the United States and Canada) collaborate to arrange this event.
The annual Bionomics-MSD symposium is in its fifthyear and has demonstrated year on year growth in participation numbers. Last year’s event entitled Frontiers in Neuroscience Research: Memory, Movement and Mood attracted over 200 delegates including researchers, medical personnel, patient support groups, life science analysts and investors. The purpose of this event continues to focus on the importance of finding suitable treatment options for cognitive conditions and keeping participants informed of the latest advances.
The symposium will be opened by Bionomics CEO and Managing Director, Dr Deborah Rathjen and closed by Mr Ben Thorner, Senior Vice President, Business Development & Licensing at MSD.
Some of the key presentations at the symposium this year will be;
There will be emphasis upon the treatment of post-traumatic stress disorder (PTSD) at the symposium this year with Professor Malcolm Hopwood, Ramsay Health Care Professor of Psychiatry, University of Melbourne on PTSD: Treatment Opportunities. This presentation will be followed by Dr Sue O’Connor VP Neuroscience from Bionomics who will present an overview on lead drug candidate BNC210 and its potential as a viable anxiolytic – A Novel Therapeutic in Development for PTSD.
Please find the full program below, registration is free of charge and interested individuals can contact Dr Lauren Nicotra, Senior Associate, Strategic Alliances at email@example.com to enquire about registration.
5th Annual Symposium – The Frontiers of Neuroscience: Feelings & Forgetting
Adelaide Convention Centre, North Terrace, Adelaide, Thursday 26 October 2017
|9.15||Dr Deborah Rathjen
CEO & Managing Director, Bionomics
|9.30||Professor Steve Williams
IoPPN Kings College London & Maudsley Hospital
|MR Neuroimaging to Facilitate the Drug R&D Process – from Mouse to Man|
|10.00||Dr Ann Hayes
The Ann Hayes Consultancy; formerly Director of CNS Therapeutic Research, GlaxoWellcome
|Multiple Mechanisms for Pain – How Can We Improve the Chances of Success?|
|10.30 MORNING TEA
|11.00||Dr Richard Hargreaves
Corporate Vice President Neuroscience & Imaging, Celgene
|Seeing the Problems and Devising Solutions for Neurodegenerative Disease|
|11.30||Professor Ole Isaacson
Professor of Neurology & Neuroscience,
Harvard Medical School
|Novel Concepts from Human Cell Biology and Genetics for Neurodegenerative Disease Treatments|
|12.00||Dr Michael F Egan
Associate Vice President, Clinical Neuroscience, MSD
|Development of BACE Inhibitors for the Treatment of Alzheimer’s Disease|
|1.30||Dr Paul Coleman
Executive Director, Discovery Chemistry, MSD
|Discovery of Belsomra, a First-in-Class Orexin Antagonist for the Treatment of Insomnia|
|2.00||Professor Alexander McFarlane
Director of the Centre for Traumatic Stress Studies, Professor of Psychiatry, University of Adelaide
|The Importance of a Staging Approach to Psychiatric Illness in Understanding the Role of Biomarkers and Treatment Response|
|2.30||Professor Paul Rolan
Director of Innovation, University of Adelaide
|Innovation in Clinical Trial Design|
|3.00 AFTERNOON TEA
|3.30||Professor Malcolm Hopwood
Ramsay Health Care Professor of Psychiatry,
University of Melbourne
|PTSD: Treatment Opportunities|
|4.00||Dr Sue O’Connor
VP Neuroscience, Bionomics
|BNC210 – A Novel Therapeutic in Development for PTSD|
|4.30||Mr Ben Thorner
Senior Vice President, Business Development & Licensing, MSD
4.45-5.45 NETWORKING WITH DRINKS & CANAPES